lyophilization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
To help the players develop the fictional history of Aperture Science, Valve created a digital comic to tell the story of the "Rat Man", a schizophrenic who is unseen in the games themselves but creates murals and scrawlings that guide Chell in both games. The comic, "Portal 2: Lab Rat", takes place both during and after Portal, explaining the events that led to Portal 2. The Rat Man's artwork appears early in Portal 2, where it retells the plot of Portal. Michael Avon Oeming, who had worked on comics for Valve games Team Fortress 2 and Left 4 Dead, and Valve in-house artist Andrea Wicklund drew the comic. Ted Kosmatka wrote most of the story with input from the Portal 2 writers. The 27-page comic was made available online in two parts about two weeks before the game's release and was also bundled with the game itself. Dark Horse Comics has published "Portal 2: Lab Rat" in a printed anthology of Valve comics, Valve Presents: The Sacrifice and Other Steam-Powered Stories, in November 2011. In the comic, Doug Rattmann (also known as The Rat Man) is a scientist working in the Aperture facility. He escapes GLaDOS's initial neurotoxin attack, but suffers symptoms as his schizophrenia medication runs out, causing hallucinations of his Weighted Companion Cube talking. Noticing that Chell is uniquely tenacious among the test subjects held by Aperture, Rattmann moves her to the top of the queue of testing subjects, thus starting the events of the first Portal.
=== General mixtures === Insulin mixtures can sometimes be combined in a single syringe, such as when mixing intermediate-acting insulin with rapid- or short-acting insulin. However, not all types of insulin are compatible for mixing. For convenience, there are premixed formulations of rapid- and intermediate-acting insulins. These come in fixed ratios like 75/25, 70/30, or 50/50. For example, a 75/25 mix contains 75% intermediate-acting insulin and 25% rapid-acting insulin. These are typically injected twice a day at the start of meals. The mixture appears cloudy, and it begins to work as quickly as the rapid-acting insulin, but it lasts as long as the intermediate-acting insulin.
=== Immune system === Immune cells of both the innate immune system and adaptive immune systems frequently express the α2, α5, α6, α7, α9, and α10 subunits of nicotinic acetylcholine receptors. Evidence suggests that nicotinic receptors which contain these subunits are involved in the regulation of immune function. Although some of its effects are pro-inflammatory (e.g., inducing prostaglandin E2 production), nicotine effects are mostly anti-inflammatory. Nicotine suppresses the innate and adaptive immune response by reducing the secretion of pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IL-17, IL-21, and IL-22), reducing proliferation and activation of T-cells, and suppressing the activation of dendritic cells. As a result, cell-mediated immunity against infection and neoplastic diseases is downregulated. In vitro and animal studies also showed that nicotine reduces T cell receptor (TCR) signaling and suppresses the production and secretion of antibodies. Nicotine effects on immune system function can aggravate tumors (growth and metastases) in cancer patients and is found to have many positive effects in the treating autoimmune disease (e.g. inflammatory bowel disease/ulcerative colitis, arthritis), requiring further studies.
Sources: en.wikipedia.org
=== Acid coagulants === Glucono delta-lactone (GDL) is a naturally occurring organic acid also used in cheesemaking, this coagulant produces a very fine textured tofu that is almost jelly-like. It is used especially for "silken" and softer tofus and confers a faint sour taste to the finished product. GDL is derived from glucose and takes the form of a white powder at room temperature. Its molecular structure contains a six-membered heterocyclic ring that is hydrolyzed upon contact with water, slowly converting GDL to gluconic acid. When added to soy milk, it gradually lowers the pH and causes proteins to coagulate evenly throughout the mixture, forming a single, smooth gel that is free of air gaps and that resists breaking during transportation. Using GDL as a coagulant, silken tofu can be formed directly in its container, as it does not require pressing. This acid coagulant is also commonly used together with calcium sulfate to give soft tofu a smooth, tender texture. Other edible acids can be used. Though they can affect the taste of the tofu more, and vary in density and texture, acids such as acetic acid (vinegar) and citric acid (such as lemon juice), can also be used to coagulate soy milk and produce tofu.
== Further reading == Bolsmann, Chris (1 November 2021). "'Playing With Apartheid': Irish and South African Rugby, 1964–19891". Sport History Review. 52 (2): 262–278. doi:10.1123/shr.2020-0027. S2CID 235043351. Booth, Douglas (1 July 2003). "Hitting Apartheid for Six? The Politics of the South African Sports Boycott". Journal of Contemporary History. 38 (3): 477–493. doi:10.1177/0022009403038003008. S2CID 145730533. Booth, Douglas (2013). "Recapturing the Moment? Global Rugby, Economics and the Politics of Nation in Post-Apartheid South Africa". In Chandler, Timothy J.L.; Nauright, John (eds.). Making the Rugby World. pp. 181–200. doi:10.4324/9781315036984. ISBN 978-1-135-22722-7. Nixon, Rob (1992). "Apartheid on the Run: The South African Sports Boycott". Transition (58): 68–88. doi:10.2307/2934968. JSTOR 2934968. Snyders, Hendrik (3 July 2018). "'An Outrage, Not Athletics': Apartheid and South African–United States Rugby Relations, 1976–1990". The International Journal of the History of Sport. 35 (10): 1029–1059. doi:10.1080/09523367.2019.1576636. S2CID 150831234. Snyders, Hendrik (2022). "Rugby, reconciliation, and post-apartheid public memory". Sport in Museums. pp. 80–91. doi:10.4324/9781351117944-6. ISBN 978-1-351-11794-4.
somatic cell Also vegetal cell or soma. Any biological cell forming the body of an organism, or, in multicellular organisms, any cell other than a gamete, germ cell, or undifferentiated stem cell. Somatic cells are theoretically distinct from cells of the germ line, meaning the mutations they have undergone can never be transmitted to the organism's descendants, though in practice exceptions do exist.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.